Nuveen’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,103,840
| Closed | -$815K | – | 3299 |
|
|
2024
Q4 | $815K | Hold |
1,103,840
| – | – | ﹤0.01% | 2792 |
|
|
2024
Q3 | $1.73M | Buy |
1,103,840
+887,574
| +410% | +$1.58M | ﹤0.01% | 2489 |
|
|
2024
Q2 | $363K | Sell |
216,266
-307,911
| -59% | -$552K | ﹤0.01% | 3097 |
|
|
2024
Q1 | $1.26M | Buy |
524,177
+113,131
| +28% | +$243K | ﹤0.01% | 2602 |
|
|
2023
Q4 | $629K | Buy |
411,046
+1,867
| +0.5% | +$2.22K | ﹤0.01% | 2931 |
|
|
2023
Q3 | $446K | Buy |
409,179
+89,985
| +28% | +$158K | ﹤0.01% | 2878 |
|
|
2023
Q2 | $731K | Buy |
319,194
+117,680
| +58% | +$312K | ﹤0.01% | 2793 |
|
|
2023
Q1 | $489K | Sell |
201,514
-43,136
| -18% | -$98.8K | ﹤0.01% | 2812 |
|
|
2022
Q4 | $467K | Sell |
244,650
-61,866
| -20% | -$132K | ﹤0.01% | 2900 |
|
|
2022
Q3 | $736K | Buy |
306,516
+56,582
| +23% | +$157K | ﹤0.01% | 2862 |
|
|
2022
Q2 | $465K | Buy |
249,934
+6,054
| +2% | +$11.6K | ﹤0.01% | 3037 |
|
|
2022
Q1 | $530K | Buy |
243,880
+1,527
| +0.6% | +$4.23K | ﹤0.01% | 2994 |
|
|
2021
Q4 | $904K | Sell |
242,353
-340,947
| -58% | -$1.66M | ﹤0.01% | 2891 |
|
|
2021
Q3 | $2.83M | Sell |
583,300
-85,183
| -13% | -$350K | ﹤0.01% | 2511 |
|
|
2021
Q2 | $3.07M | Buy |
668,483
+222,456
| +50% | +$1.07M | ﹤0.01% | 2502 |
|
|
2021
Q1 | $2.62M | Buy |
446,027
+233,728
| +110% | +$1.62M | ﹤0.01% | 2490 |
|
|
2020
Q4 | $726K | Buy |
212,299
+11,415
| +6% | +$21.8K | ﹤0.01% | 2918 |
|
|
2020
Q3 | $289K | Hold |
200,884
| – | – | ﹤0.01% | 3098 |
|
|
2020
Q2 | $401K | Buy |
200,884
+30,367
| +18% | +$59.5K | ﹤0.01% | 2975 |
|
|
2020
Q1 | $332K | Buy |
170,517
+11,891
| +7% | +$35.4K | ﹤0.01% | 2903 |
|
|
2019
Q4 | $658K | Sell |
158,626
-15,081
| -9% | -$58.1K | ﹤0.01% | 2833 |
|
|
2019
Q3 | $522K | Sell |
173,707
-8,496
| -5% | -$26.3K | ﹤0.01% | 2933 |
|
|
2019
Q2 | $1.15M | Buy |
+182,203
| New | +$1.09M | ﹤0.01% | 2680 |
|
|
2015
Q2 | – | Sell |
-2,532
| Closed | -$17K | – | 1625 |
|
|
2015
Q1 | $17K | Sell |
2,532
-5,235
| -67% | -$35.7K | ﹤0.01% | 1576 |
|
|
2014
Q4 | $49K | Sell |
7,767
-174
| -2% | -$1.4K | ﹤0.01% | 1584 |
|
|
2014
Q3 | $78K | Hold |
7,941
| – | – | ﹤0.01% | 1550 |
|
|
2014
Q2 | $89K | Hold |
7,941
| – | – | ﹤0.01% | 1558 |
|
|
2014
Q1 | $96K | Hold |
7,941
| – | – | ﹤0.01% | 1544 |
|
|
2013
Q4 | $100K | Buy |
7,941
+196
| +3% | +$3.12K | ﹤0.01% | 1522 |
|
|
2013
Q3 | $129K | Buy |
7,745
+171
| +2% | +$2.87K | ﹤0.01% | 1421 |
|
|
2013
Q2 | $115K | Buy |
+7,574
| New | +$115K | ﹤0.01% | 1483 |
|
Other funds holding LXRX
AG
SL
SSA
Nuveen's LXRX Position: Q1 2025 in Review
Nuveen sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 1,103,840 shares — an estimated $815K sold.
Nuveen first reported a position in LXRX in Q2 2013 and held it in 31 quarters. The position peaked at $3.07M in Q2 2021. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.
- Nuveen reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Nuveen sold 1,103,840 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $815K.
- Nuveen first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 31 quarters.
- Nuveen's Lexicon Pharmaceuticals position peaked at $3.07M in Q2 2021.
- 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.
Based on Nuveen's 13F filing for Q1 2025, filed 12 May 2025.